Bruker Launches MyGenius PRO® Molecular Diagnostics System in Europe
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy BRKR?
Source: Newsfilter
- Product Launch: Bruker announces the European launch of MyGenius PRO®, a fully automated sample-to-answer molecular diagnostics system based on PCR technology, designed to enhance efficiency in infectious disease testing by supporting higher throughput and random-access operation, thereby meeting laboratory demands for high-volume testing.
- Menu Expansion Plans: The MyGenius PRO® IVDR menu will initially include assays for Cytomegalovirus (CMV) and Epstein-Barr virus (EBV), with rapid expansion planned throughout 2026 to include tests for HIV-1, HBV, and HCV, thereby enhancing diagnostic support for immunocompromised patients.
- Collaborative Development: The platform was developed in collaboration between Bruker's ELITechGroup and Hitachi High-Tech, combining expertise in molecular assays, automation, and engineering, and is expected to be introduced in Japan under the name LABOSPECT GA-5, further expanding market reach.
- Industry Impact: Dr. Pierangelo Clerici, President of AMCLI, emphasized the critical importance of high throughput in microbiology laboratories, stating that fully automated sample-to-result solutions improve turnaround times, support faster clinical responses, and enhance infection monitoring, thereby streamlining laboratory workflows.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BRKR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BRKR
Wall Street analysts forecast BRKR stock price to rise
12 Analyst Rating
7 Buy
4 Hold
1 Sell
Moderate Buy
Current: 40.700
Low
40.00
Averages
52.18
High
60.00
Current: 40.700
Low
40.00
Averages
52.18
High
60.00
About BRKR
Bruker Corporation is a developer, manufacturer and distributor of high-performance scientific instruments and analytical and diagnostic solutions. The Company's segments include Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies (BEST). Its BSI segment designs, manufactures and distributes life science tools based on magnetic resonance technology and offers automated laboratory research and development solutions in chemical research fields. Its BSI CALID segment designs, manufactures and distributes life science mass spectrometry, applied spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies. BSI NANO designs, manufactures and distributes advanced x-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bruker Spatial Biology Unveils New Platforms at AACR 2026
- New Platform Launch: Bruker Corporation unveiled cross-platform workflows linking GeoMx and CellScape at the AACR 2026 meeting, showcasing the first-of-its-kind 208-plex CellScape XR spatial proteomics datasets aimed at accelerating oncology research.
- Dataset Innovation: The newly launched 208-plex datasets, developed in collaboration with the University Medical Center Schleswig-Holstein, demonstrate the application potential of CellScape XR in tumor biology and immune contexture, enhancing research depth for clinical applications.
- PaintScape Platform: Bruker's PaintScape platform enables high-precision visualization of the 3D genome in single cells, launching the 419-plex ChromoPaint HuCL PanChromo MPX panel to help researchers understand the relationship between genome structure and disease.
- Multiomics Integration: The GeoMx DSP platform is the first to integrate spatial multiomics data across RNA pathways, proteins, and post-translational modifications, facilitating seamless connections for biomarker discovery and clinical validation.
See More
Bruker Launches MBT Easy T®Kit and Expands Libraries
- Product Innovation: Bruker introduces the MBT Easy T®Kit, providing a standardized sample transfer solution that supports processing up to 2,000 samples, significantly enhancing laboratory operational efficiency and reducing chemical waste, thereby optimizing the microbial identification workflow.
- Library Expansion: The MALDI Biotyper® reference library expands to over 5,300 species with the addition of 600 new species, particularly enhancing coverage for filamentous fungi, which strengthens the product's market competitiveness and application range.
- Cloud Solution: Bruker offers early access to a cloud-based MALDI identification solution for key opinion leaders, allowing research use of expert-curated specialist libraries, enhancing laboratory flexibility and data accessibility while supporting future technological advancements.
- Clinical Research: Bruker is conducting multiple clinical validation studies with plans to submit FDA applications for mycobacteria and filamentous fungi identification by 2026, promoting the clinical application of rapid antimicrobial susceptibility testing and reinforcing the company's leadership in microbiology.
See More
Bruker Launches MyGenius PRO® Molecular Diagnostics System in Europe
- Product Launch: Bruker announces the European launch of MyGenius PRO®, a fully automated sample-to-answer molecular diagnostics system based on PCR technology, designed to enhance efficiency in infectious disease testing by supporting higher throughput and random-access operation, thereby meeting laboratory demands for high-volume testing.
- Menu Expansion Plans: The MyGenius PRO® IVDR menu will initially include assays for Cytomegalovirus (CMV) and Epstein-Barr virus (EBV), with rapid expansion planned throughout 2026 to include tests for HIV-1, HBV, and HCV, thereby enhancing diagnostic support for immunocompromised patients.
- Collaborative Development: The platform was developed in collaboration between Bruker's ELITechGroup and Hitachi High-Tech, combining expertise in molecular assays, automation, and engineering, and is expected to be introduced in Japan under the name LABOSPECT GA-5, further expanding market reach.
- Industry Impact: Dr. Pierangelo Clerici, President of AMCLI, emphasized the critical importance of high throughput in microbiology laboratories, stating that fully automated sample-to-result solutions improve turnaround times, support faster clinical responses, and enhance infection monitoring, thereby streamlining laboratory workflows.
See More
Bruker's MBT Easy T® Kit Enhances Microbial Identification
- Product Innovation: Bruker has launched the MBT Easy T® Kit, which provides ready-to-use solvents and sample applicators, supporting standardized transfer for up to 2,000 samples, significantly simplifying the sample preparation process for MALDI Biotyper®, thereby enhancing laboratory efficiency and accuracy.
- Database Expansion: The MALDI Biotyper® reference library has expanded to over 5,300 species with the addition of 600 new species, particularly strengthening coverage for filamentous fungi, which is expected to improve the accuracy and breadth of clinical microbial identification to meet growing market demands.
- Cloud Solution: Bruker is offering a cloud-based MALDI identification solution for key opinion leaders, allowing research identification using expert-curated specialist libraries, enhancing laboratory flexibility and data access capabilities while supporting future technological developments.
- Clinical Research Progress: Bruker is conducting multiple clinical validation studies aimed at submitting FDA applications in 2026 to support identification claims for mycobacteria and filamentous fungi, advancing the clinical application of rapid antimicrobial susceptibility testing to enhance hospital infection control capabilities.
See More
Bruker Unveils New NMR Products at Conference
- New Product Launch: Bruker introduced new Nuclear Magnetic Resonance (NMR) products and workflow solutions at the Experimental Nuclear Magnetic Resonance Conference, aimed at enhancing performance, sensitivity, and automation in research and applied NMR fields, which is expected to significantly improve research efficiency and data accuracy for scientists and technicians.
- Positive Market Reaction: The company's stock rose 4% post-announcement to $39.08, although Bruker has experienced 22 moves greater than 5% in the past year, indicating that while the market considers this news significant, it does not fundamentally alter perceptions of the business.
- Poor Long-Term Performance: Bruker is down 18.8% year-to-date and is currently trading 28.2% below its 52-week high of $54.46, suggesting that despite the new product launch, investor confidence in the company's future remains low.
- Investor Concerns: If investors had purchased $1,000 worth of Bruker shares five years ago, it would now be worth only $566.57, reflecting the company's underperformance in the market and indicating a potential need for reassessment of its investment value.
See More
Bruker Corporation Unveils New NMR Products and Solutions
- New Product Launch: At the Experimental NMR Conference, Bruker Corporation introduced several new NMR products, including the high-performance AVANCE NEO-X console and Advanced Chemical Profiling 2.0 software, aimed at enhancing laboratory performance and automation, thereby improving research efficiency and data accuracy.
- Automated Workflows: The Advanced Chemical Profiling 2.0 software supports a fully automated workflow from data acquisition to reporting by reducing manual interpretation, particularly benefiting small-molecule pharmaceutical and industrial applications, which is expected to significantly enhance the quantitative accuracy of multicomponent spectra.
- DNP Technology Expansion: Bruker expanded its DNP portfolio with new standard-bore DNP probes that enable ultra-high sensitivity on 600 and 800 MHz magnets, which is anticipated to drive advancements in biosolid applications research.
- AI-Assisted Analysis: The NMRtist software provides AI-assisted protein NMR data analysis, simplifying multidimensional peak picking and resonance assignment processes, enabling non-NMR experts to use it efficiently, thus further advancing research in structural biology and drug discovery.
See More
Bruker Spatial Biology Unveils New Platforms at AACR 2026
- New Platform Launch: Bruker Corporation unveiled cross-platform workflows linking GeoMx and CellScape at the AACR 2026 meeting, showcasing the first-of-its-kind 208-plex CellScape XR spatial proteomics datasets aimed at accelerating oncology research.
- Dataset Innovation: The newly launched 208-plex datasets, developed in collaboration with the University Medical Center Schleswig-Holstein, demonstrate the application potential of CellScape XR in tumor biology and immune contexture, enhancing research depth for clinical applications.
- PaintScape Platform: Bruker's PaintScape platform enables high-precision visualization of the 3D genome in single cells, launching the 419-plex ChromoPaint HuCL PanChromo MPX panel to help researchers understand the relationship between genome structure and disease.
- Multiomics Integration: The GeoMx DSP platform is the first to integrate spatial multiomics data across RNA pathways, proteins, and post-translational modifications, facilitating seamless connections for biomarker discovery and clinical validation.
See More
Bruker Launches MBT Easy T®Kit and Expands Libraries
- Product Innovation: Bruker introduces the MBT Easy T®Kit, providing a standardized sample transfer solution that supports processing up to 2,000 samples, significantly enhancing laboratory operational efficiency and reducing chemical waste, thereby optimizing the microbial identification workflow.
- Library Expansion: The MALDI Biotyper® reference library expands to over 5,300 species with the addition of 600 new species, particularly enhancing coverage for filamentous fungi, which strengthens the product's market competitiveness and application range.
- Cloud Solution: Bruker offers early access to a cloud-based MALDI identification solution for key opinion leaders, allowing research use of expert-curated specialist libraries, enhancing laboratory flexibility and data accessibility while supporting future technological advancements.
- Clinical Research: Bruker is conducting multiple clinical validation studies with plans to submit FDA applications for mycobacteria and filamentous fungi identification by 2026, promoting the clinical application of rapid antimicrobial susceptibility testing and reinforcing the company's leadership in microbiology.
See More
Bruker Launches MyGenius PRO® Molecular Diagnostics System in Europe
- Product Launch: Bruker announces the European launch of MyGenius PRO®, a fully automated sample-to-answer molecular diagnostics system based on PCR technology, designed to enhance efficiency in infectious disease testing by supporting higher throughput and random-access operation, thereby meeting laboratory demands for high-volume testing.
- Menu Expansion Plans: The MyGenius PRO® IVDR menu will initially include assays for Cytomegalovirus (CMV) and Epstein-Barr virus (EBV), with rapid expansion planned throughout 2026 to include tests for HIV-1, HBV, and HCV, thereby enhancing diagnostic support for immunocompromised patients.
- Collaborative Development: The platform was developed in collaboration between Bruker's ELITechGroup and Hitachi High-Tech, combining expertise in molecular assays, automation, and engineering, and is expected to be introduced in Japan under the name LABOSPECT GA-5, further expanding market reach.
- Industry Impact: Dr. Pierangelo Clerici, President of AMCLI, emphasized the critical importance of high throughput in microbiology laboratories, stating that fully automated sample-to-result solutions improve turnaround times, support faster clinical responses, and enhance infection monitoring, thereby streamlining laboratory workflows.
See More
Bruker's MBT Easy T® Kit Enhances Microbial Identification
- Product Innovation: Bruker has launched the MBT Easy T® Kit, which provides ready-to-use solvents and sample applicators, supporting standardized transfer for up to 2,000 samples, significantly simplifying the sample preparation process for MALDI Biotyper®, thereby enhancing laboratory efficiency and accuracy.
- Database Expansion: The MALDI Biotyper® reference library has expanded to over 5,300 species with the addition of 600 new species, particularly strengthening coverage for filamentous fungi, which is expected to improve the accuracy and breadth of clinical microbial identification to meet growing market demands.
- Cloud Solution: Bruker is offering a cloud-based MALDI identification solution for key opinion leaders, allowing research identification using expert-curated specialist libraries, enhancing laboratory flexibility and data access capabilities while supporting future technological developments.
- Clinical Research Progress: Bruker is conducting multiple clinical validation studies aimed at submitting FDA applications in 2026 to support identification claims for mycobacteria and filamentous fungi, advancing the clinical application of rapid antimicrobial susceptibility testing to enhance hospital infection control capabilities.
See More
Bruker Unveils New NMR Products at Conference
- New Product Launch: Bruker introduced new Nuclear Magnetic Resonance (NMR) products and workflow solutions at the Experimental Nuclear Magnetic Resonance Conference, aimed at enhancing performance, sensitivity, and automation in research and applied NMR fields, which is expected to significantly improve research efficiency and data accuracy for scientists and technicians.
- Positive Market Reaction: The company's stock rose 4% post-announcement to $39.08, although Bruker has experienced 22 moves greater than 5% in the past year, indicating that while the market considers this news significant, it does not fundamentally alter perceptions of the business.
- Poor Long-Term Performance: Bruker is down 18.8% year-to-date and is currently trading 28.2% below its 52-week high of $54.46, suggesting that despite the new product launch, investor confidence in the company's future remains low.
- Investor Concerns: If investors had purchased $1,000 worth of Bruker shares five years ago, it would now be worth only $566.57, reflecting the company's underperformance in the market and indicating a potential need for reassessment of its investment value.
See More
Bruker Corporation Unveils New NMR Products and Solutions
- New Product Launch: At the Experimental NMR Conference, Bruker Corporation introduced several new NMR products, including the high-performance AVANCE NEO-X console and Advanced Chemical Profiling 2.0 software, aimed at enhancing laboratory performance and automation, thereby improving research efficiency and data accuracy.
- Automated Workflows: The Advanced Chemical Profiling 2.0 software supports a fully automated workflow from data acquisition to reporting by reducing manual interpretation, particularly benefiting small-molecule pharmaceutical and industrial applications, which is expected to significantly enhance the quantitative accuracy of multicomponent spectra.
- DNP Technology Expansion: Bruker expanded its DNP portfolio with new standard-bore DNP probes that enable ultra-high sensitivity on 600 and 800 MHz magnets, which is anticipated to drive advancements in biosolid applications research.
- AI-Assisted Analysis: The NMRtist software provides AI-assisted protein NMR data analysis, simplifying multidimensional peak picking and resonance assignment processes, enabling non-NMR experts to use it efficiently, thus further advancing research in structural biology and drug discovery.
See More
